Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TNF | P01375 | 7/20 | 0.45 |
| ▸ | ALPL | P05186 | 2/20 | 0.43 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALPG | P10696 | 1/20 | 0.43 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.41 |
| ▸ | QPCT | Q16769 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL36488 | 0.87 | CYP1A2 (0.46) | LMNAALPLPLAAALDH1A1ALPG | |
| SCHEMBL28813539 | 0.85 | QPCT (0.45) | ALPLPLAAALDH1A1ALPGKAT2B | |
| SCHEMBL28403089 | 0.84 | TSHR (0.41) | LMNATNFALPLPLAAALDH1A1 | |
| SCHEMBL3711683 | 0.83 | RAB9A (0.54) | LMNAALPLPLAAALDH1A1ALPG | |
| SCHEMBL28290763 | 0.80 | MITF (0.52) | LMNATNFALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL28796556 | 0.80 | ALPL (0.48) | ALPLPLAAALPGQPCT | |
| SCHEMBL4418553 | 0.79 | ALDH1A1 (0.59) | LMNAALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL1178282 | 0.78 | ALPL (0.47) | ALPLPLAAALPGQPCT | |
| SCHEMBL23959823 | 0.76 | TNF (0.48) | LMNATNFTBXAS1 | |
| SCHEMBL29852373 | 0.75 | TNF (0.47) | LMNATNFTBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105439908-B | The method that one kind catalyzes and synthesizes N, N ' 2-substituted carbamides derivative and imdazole derivatives | 台州学院 | 2017-10-03 | — | — | CN | disclosed |
| CN-105439908-A | Method for catalytically synthesizing N, N'-disubstituted urea derivative and imidazole derivative | UNIV TAIZHOU | 2016-03-30 | — | — | CN | disclosed |
| US-8492384-B2 | Imidazolylalkylcarbonyl derivatives as calcium channel modulators and preparation method thereof | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-07-23 | — | — | US | disclosed |
| US-7763728-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-07-27 | — | — | US | disclosed |
| US-7714136-B2 | Tetrahydropyridothiophenes | 4SC AG (DE) | 2010-05-11 | — | — | US | disclosed |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2009-12-31 | — | — | US | disclosed |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | PEKARI KLAUS | 2009-10-15 | — | — | US | disclosed |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-10-23 | — | — | US | disclosed |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | NYCOMED GMBH (DE) | 2008-08-28 | — | — | US | disclosed |
| EP-1896484-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-12 | — | — | EP | disclosed |
| EP-1893618-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | Nycomed GmbH (DE) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006125815-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
| WO-2006125813-A2 | TETRAHYDROPYRIDOTHIOPHENES FOR USE IN THE TREATMENT OF CANCER | NYCOMED GMBH (DE) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090257977-A1 | NOVEL TETRAHYDROPYRIDOTHIOPHENES | BAX, BCL2, CCAR2 | LMNA 4066/4885TNF 213/4885ALPL 4099/4885 |
| US-20080260749-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | LMNA 3874/4885TNF 178/4885ALPL 4077/4885 |
| US-20080206258-A1 | Novel Tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | LMNA 3874/4885TNF 178/4885ALPL 4077/4885 |
| US-20090325979-A1 | NOVEL IMIDAZOLYLALKYLCARBONYL DERIVATIVES AS CALCIUM CHANNEL MODULATORS AND PREPARATION METHOD THEREOF | CACNA1B, CACNA1C, ORAI1 | LMNA 936/4885TNF 4685/4885ALPL 2767/4885 |
| US-20090258873-A1 | Novel tetrahydropyridothiophenes | BAX, BCL2, CCAR2 | LMNA 4066/4885TNF 213/4885ALPL 4099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.